GlaxoSmithKline (GSK) and Singapore's Institute of Chemical and Engineering Sciences (ICES) signed a five-year deal to develop evidence-based formulations (EBFs) for emerging markets such as China, Brazil, India and Russia.
"EBFs are an important part of our growth strategy, and our hope is that together with ICES we will create a sustainable, scalable model to meet both specific market conditions and patient requirements," said Duncan McKay, vice president, Emerging Markets & Asia Pacific R&D, GSK.
EBFs refer to pharmaceutical products that are created after two or more drugs have been combined.
The collaboration can help enhance ICES' technical expertise and know-how in drug product formulation, analytical techniques, development and scale up. ICES is a research arm under the Singapore government's scientific body A*STAR.
ICES management believes that the research work will create a pool of local expertise in specialised formulation for pharmaceutical development in Singapore.
"This venture will enable us to develop future scientists and laboratory analysts with the right skills to grow this industry in Singapore," said Dr Keith Carpenter, executive director, ICES.
"This is a strong endorsement of Singapore's scientific talent and capabilities. It also further reinforces Singapore's offering as the base for companies to generate insights and develop new solutions and market access strategies for the fast growing emerging markets," said Kevin Lai, director, Biomedical Sciences, Singapore Economic Development Board.
Sign up for CIO Asia eNewsletters.